Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page
- CheckyesterdayChange DetectedThe page revision updates from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.1%
- Check9 days agoChange DetectedThe page has updated the citation for the ENHANCE-2 study, changing the publication date and revision number.SummaryDifference0.3%
- Check16 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as additional drug information and publications related to acute myeloid leukemia. Some previous entries have been removed, including certain location details and drug information.SummaryDifference10%
- Check23 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.3%
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.4%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.